Dr. Cynthia Gagnon Receives 2024 Steinert Award, IDMC-15 Meeting to Take Place in Saguenay 

We are pleased to share that NMD4C steering committee member Dr. Cynthia Gagnon was honoured with a Steinert Clinical Sciences Award at the recent International Myotonic Dystrophy Consortium Meeting (IDMC-14) in Nijmegen, Netherlands! 

The prestigious Steinert awards are presented to individuals who display excellence in clinical and basic research on myotonic dystrophy. Based in Québec’s Saguenay-Lac-Saint-Jean region, an area with an elevated prevalence of Myotonic dystrophy (DM1) where 1:600 people are affected by the disease, Dr. Gagnon is the scientific director of the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN) where she leads research projects and clinical trials on a variety of NMDs, including DM1. Dr. Gagnon has established an internationally renowned research program focused on documenting the natural history of NMDs through an interdisciplinary perspective to document disease progression and identify significant predictor and explanatory factors related to participation in daily activities and social roles of patients, and defining the best outcome measures to assess potential therapeutic targets. Dr. Gagnon is a key figure in growing the number of clinical trials available in Canada for DM1, facilitating trials at sites in Saguenay-Lac-Saint-Jean and collaborating with Dr. Hanns Lochmüller’s research team in Ottawa. 

 

Saguenay Prepares to Welcome International Colleagues to IDMC-15 in 2026 

Dr. Gagnon and GRIMN will host the 15th edition of the IDMC in Saguenay, QC in the fall of 2026 

We look forward to welcoming the leading international myotonic dystrophy conference to Canada, and will share further news on the meeting as details are available. 

IDMC-14_steinertaward_Cynthia_4x3

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.